NEW YORK--(BUSINESS WIRE)--Bristol-Myers
Squibb Company (NYSE:BMY) announced today that it has completed its
previously announced divestment of its oral solid, biologics, and
sterile product manufacturing and packaging facility in Anagni, Italy,
to Catalent Inc.
The divestiture is part of Bristol-Myers Squibb’s strategy to simplify
and to realign its business portfolio to address changes in its business
and the future requirements of its evolving pipeline.
The Anagni facility manufactures and packages cardiovascular,
anticancer, metabolic and anti-inflammatory medicines as well as
non-penicillin-based antibiotics, antivirals, analgesics as injectables
and biologics. The Company is focusing resources on its highest
priorities of discovering, developing and delivering transformational
medicines for patients facing serious diseases.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission
is to discover, develop and deliver innovative medicines that help
patients prevail over serious diseases. For more information about
Bristol-Myers Squibb, visit us at BMS.com or
follow us on LinkedIn, Twitter,
YouTube,
Facebook
,
and Instagram.
Bristol-Myers Squibb Forward-Looking Statement
This press release contains “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of 1995
regarding, among other things, the research, development and
commercialization of pharmaceutical products and the transaction. All
statements that are not statements of historical facts are, or may be
deemed to be, forward-looking statements. Such forward-looking
statements are based on historical performance and current expectations
and projections about our future financial results, goals, plans and
objectives and involve inherent risks, assumptions and uncertainties,
including internal or external factors that could delay, divert or
change any of them in the next several years, that are difficult to
predict, may be beyond our control and could cause our future financial
results, goals, plans and objectives to differ materially from those
expressed in, or implied by, the statements. These risks, assumptions,
uncertainties and other factors include, among others, any delay or
inability of Bristol-Myers Squibb to realize the expected benefits of
the transaction. No forward-looking statement can be guaranteed.
Forward-looking statements in this press release should be evaluated
together with the many risks and uncertainties that affect Bristol-Myers
Squibb’s business and market, particularly those identified in the
cautionary statement and risk factors discussion in Bristol-Myers
Squibb’s Annual Report on Form 10-K for the year ended December 31,
2018, as updated by our subsequent Quarterly Reports on Form 10-Q,
Current Reports on Form 8-K and other filings with the Securities and
Exchange Commission. The forward-looking statements included in this
document are made only as of the date of this document and except as
otherwise required by applicable law, Bristol-Myers Squibb undertakes no
obligation to publicly update or revise any forward-looking statement,
whether as a result of new information, future events, changed
circumstances or otherwise.
Media: media@bms.com 609-252-3345 Investors: Tim Power, 609-252-7509, timothy.power@bms.com Nina Goworek, 908-673-9711, ngoworek@celgene.com